Omalizumab is effective for the control of urticaria recalcitrant to antihistamines in different populations globally. The ratio of total serum IgE 4-week/baseline ≥2 can predict response with a high likelihood. In observational real-life trials, doses have been adjusted on an individual basis: in some populations, up to two-thirds of the patients can be controlled with 150 mg/month; however, others are still not controlled with 300 mg/month. In these, 150 mg bimonthly could be tried, before up-dosing to 450 mg/month. On the long run (up to 3 years) omalizumab kept its efficacy. In many patients, dosing intervals could be augmented (6-8 weeks, some even more). After a 12-month treatment, about 20% showed long-term remission without relapse. Some biomarkers are being detected. Adjusting omalizumab doses in urticaria patients could enhance efficacy (shortening dosing interval and/or augmenting dose) and save costs (after 12 months: extending dosing interval and/or reducing dose).
Mental health is more affected than physical health in Colombian subjects with respiratory allergy. There was a strong correlation between the mental health domain and the values of PEF in patients with asthma/allergic rhinitis.
Introducción: las enfermedades alérgicas afectan la calidad de vida de quienes las padecen y en los últimos años su prevalencia ha aumentado significativamente. La inmunoterapia con extractos alergénicos es usada para mejorar el curso de la enfermedad; no obstante, aún es necesario conocer su efectividad y seguridad. Objetivo: describir las reacciones adversas sistémicas producidas por la administración de inmunoterapia subcutánea con extractos polimerizados de ácaros. Materiales y métodos: se realizó un estudio de cohorte retrospectivo de pacientes con enfermedad alérgica mediada por IgE que recibieron inmunoterapia subcutánea con extractos polimerizados de Dermatophagoides farinae, Dermatophagoides pteronyssinus y Blomia tropicalis en el servicio de Alergología Clínica de la IPS Universitaria de la Universidad de Antioquia (Medellín, Colombia). Se realizó un análisis descriptivo de las variables demográficas y clínicas y su asociación con el riesgo de reacción adversa sistémica. Resultados: se incluyeron 622 pacientes; 92,8% con diagnóstico de rinitis, 60,3% de asma, 56,9% de conjuntivitis y 19,6% de dermatitis atópica. Un total de 73 (11,7%) pacientes experimentaron reacciones sistémicas adversas (razón de reacción/inyección = 1,06 x 100 inyecciones); de estos 47 (64,4%) recibieron adrenalina intramuscular. El 93,1% de los pacientes presentaron reacciones sistémicas grado 1 y 2. El asma fue el diagnóstico con mayor riesgo de presentar reacción sistémica (riesgo relativo = 1,96). Conclusiones: la inmunoterapia subcutánea con extractos polimerizados de ácaros administrada en pacientes con enfermedad alérgica demostró ser segura. No obstante, debe ser indicada y aplicada por personal clínico experto y advertírsele al paciente sobre los posibles riesgos y efectos adversos.
The frequency of systemic reactions with subcutaneous immunotherapy with Dermatophagoides farinae, Dermatophagoides pteronyssinus and Blomia tropicalis tyrosine-adsorbed extracts was similar to that reported with other extracts.
RATIONALE: HDR are frequent motives for consultation in Allergology services. Possible etiologic factors and clinical presentation differences between Latin American children and adults have not been described yet. METHODS: An observational cross sectional study using a modified ENDA questionnaire was implemented in 19 allergology units in 11 Latin-American countries, reporting patients presenting HDR in the last year before consultation. Causal relationship was categorized according to WHO-UMC Causality Categories: certain, probable, possible, unlikely and conditional. RESULTS: 727 patients, 144 (19.8%) of them under 18 years old, presented 732 reactions. Female gender was 71.7% in adults, and 50% in children. Atopic history was present in 44.9 and 63.8% and a history of previous drug reaction in 31.9 and 36.9% of adults and children, respectively. Fourteen percent of adult, and 10.7% of children had presented previous reactions with the same drug. The clinical picture of the reaction in adults and children was angioedema in 47.9 and 48.6%, urticaria in 44.5 and 41.8%, maculopapular and macular exanthema in 20.3 and 22.6 %, erythema multiforme and SJS in 3.6 and 2.7% respectively. Certain and probable causal relationships were attributed in adults and children to NSAIDs in 55.7 and 60.3 %, beta lactams in 11.2 and 19.8%, non beta lactam antibiotics in 8.4 and 2.5 %, anticonvulsants in 3.2 and 1.7%, chemotherapy 0.8 and 2.5% of patients, respectively. CONCLUSIONS: Female sex was predominant in adults but not in children. NSAIDs and antibiotics were the drugs implicated in more than 75% of patients. Beta lactam antibiotics were more frequently involved in children.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.